Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
|
Text
mdq319.pdf - Published Version Available under License Publisher holds Copyright. Download (104kB) | Preview |
pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment of metastatic breast cancer (MBC). We carried out a multicenter, single-arm phase II trial to evaluate the toxicity and efficacy of PLD and bevacizumab as first-line treatment in MBC patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Suter, Thomas |
ISSN: |
0923-7534 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:10 |
Last Modified: |
05 Dec 2022 14:01 |
Publisher DOI: |
10.1093/annonc/mdq319 |
PubMed ID: |
20595448 |
Web of Science ID: |
000285414800011 |
BORIS DOI: |
10.7892/boris.1614 |
URI: |
https://boris.unibe.ch/id/eprint/1614 (FactScience: 203392) |
Actions (login required)
 |
Edit item |